Leadership & Pay ·
enGene Therapeutics Inc. announced a strategic restructuring plan effective June 14, 2026, involving a workforce…
ENGNenGene Therapeutics Inc.
enGene Therapeutics Inc. announced a strategic restructuring plan effective June 14, 2026, involving a workforce reduction of approximately 50% to preserve cash and streamline operations. The company expects to incur restructuring costs between $5.7 million and $6.4 million, plus $4.7 million to $5.0 million in non-cash stock-based compensation. Several key executives are departing, including Chief Medical Officer Dr. Hussein Sweiti, CFO Ryan Daws, Chief Legal Officer Lee Giguere, and Chief Strategy and Operations Officer Alex Nichols. Kathleen Richton will succeed Ryan Daws as principal financial officer effective July 16, 2026. enGene Therapeutics Inc. is a biotechnology company focused on developing gene therapy products.